DrugCite
Search

ALTABAX

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Altabax Adverse Events Reported to the FDA Over Time

How are Altabax adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Altabax, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Altabax is flagged as the suspect drug causing the adverse event.

Most Common Altabax Adverse Events Reported to the FDA

What are the most common Altabax adverse events reported to the FDA?

Application Site Irritation
165 (11.9%)
Burning Sensation
138 (9.95%)
Application Site Pain
84 (6.06%)
Pain
79 (5.7%)
Drug Ineffective
59 (4.25%)
Erythema
44 (3.17%)
Application Site Erythema
43 (3.1%)
Pruritus
40 (2.88%)
Rash
39 (2.81%)
Hypersensitivity
38 (2.74%)
Dermatitis Contact
32 (2.31%)
Show More Show More
Skin Irritation
25 (1.8%)
Crying
22 (1.59%)
Blister
20 (1.44%)
Application Site Pruritus
19 (1.37%)
Swelling
18 (1.3%)
Screaming
16 (1.15%)
Thermal Burn
13 (.94%)
Drug Administration Error
12 (.87%)
Cheilitis
9 (.65%)
Discomfort
9 (.65%)
Lip Swelling
9 (.65%)
Skin Burning Sensation
9 (.65%)
Application Site Reaction
8 (.58%)
Dermatitis
8 (.58%)
Ill-defined Disorder
8 (.58%)
Paraesthesia
8 (.58%)
Application Site Rash
7 (.5%)
Application Site Swelling
7 (.5%)
Application Site Vesicles
7 (.5%)
Infection
7 (.5%)
Skin Discolouration
7 (.5%)
Wound Complication
7 (.5%)
Application Site Inflammation
6 (.43%)
Condition Aggravated
6 (.43%)
Irritability
6 (.43%)
Nasal Discomfort
6 (.43%)
Rash Papular
6 (.43%)
Swelling Face
6 (.43%)
Urticaria
6 (.43%)
Application Site Discharge
5 (.36%)
Feeling Abnormal
5 (.36%)
Feeling Hot
5 (.36%)
Inflammation
5 (.36%)
Pain In Extremity
5 (.36%)
Rash Macular
5 (.36%)
Therapeutic Response Unexpected
5 (.36%)
Application Site Exfoliation
4 (.29%)
Dizziness
4 (.29%)
Drug Administered At Inappropriate ...
4 (.29%)
Impaired Healing
4 (.29%)
Nonspecific Reaction
4 (.29%)
Rash Vesicular
4 (.29%)
Skin Exfoliation
4 (.29%)
Skin Lesion
4 (.29%)
Adverse Drug Reaction
3 (.22%)
Adverse Event
3 (.22%)
Application Site Burn
3 (.22%)
Application Site Discomfort
3 (.22%)
Application Site Paraesthesia
3 (.22%)
Application Site Scar
3 (.22%)
Arthralgia
3 (.22%)
Epistaxis
3 (.22%)
Impetigo
3 (.22%)
Insomnia
3 (.22%)
Medication Error
3 (.22%)
Off Label Use
3 (.22%)
Product Quality Issue
3 (.22%)
Pyrexia
3 (.22%)
Rash Generalised
3 (.22%)
Skin Disorder
3 (.22%)
Skin Injury
3 (.22%)
Skin Ulcer
3 (.22%)
Vulvovaginal Burning Sensation
3 (.22%)
Wound
3 (.22%)
Wound Secretion
3 (.22%)
Adverse Reaction
2 (.14%)
Angioedema
2 (.14%)
Anosmia
2 (.14%)
Application Site Abscess
2 (.14%)
Application Site Discolouration
2 (.14%)
Application Site Eczema
2 (.14%)
Application Site Infection
2 (.14%)
Application Site Urticaria
2 (.14%)
Application Site Warmth
2 (.14%)
Auricular Swelling
2 (.14%)
Cellulitis
2 (.14%)
Deafness Unilateral
2 (.14%)
Decreased Interest
2 (.14%)
Drug Hypersensitivity
2 (.14%)
Dyspnoea
2 (.14%)
Ear Discomfort
2 (.14%)
Ear Disorder
2 (.14%)
Eczema
2 (.14%)
Erythema Multiforme
2 (.14%)
Eye Disorder
2 (.14%)
Fungal Infection
2 (.14%)
Fungal Skin Infection
2 (.14%)
Furuncle
2 (.14%)
Haemorrhage
2 (.14%)
Headache
2 (.14%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Altabax, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Altabax is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Altabax

What are the most common Altabax adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Altabax, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Altabax is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Altabax According to Those Reporting Adverse Events

Why are people taking Altabax, according to those reporting adverse events to the FDA?

Drug Use For Unknown Indication
125
Impetigo
95
Staphylococcal Infection
39
Wound
23
Skin Infection
21
Infection
17
Show More Show More
Rash
15
Wound Infection
11
Open Wound
9
Skin Lesion
7
Laceration
6
Blister
5
Product Used For Unknown Indication
5
Infection Prophylaxis
4
Prophylaxis
4
Eczema
3
Biopsy
3
Skin Irritation
3
Cellulitis
3
Genital Rash
3
Pruritus
3
Postoperative Wound Infection
3
Fungal Infection
2
Bite
2
Skin Bacterial Infection
2
Skin Disorder
2
Dermatitis
2
Eye Disorder
2
Peritonitis Bacterial
2
Bacterial Infection
2
Fungal Skin Infection
2
Cyst
2
Excoriation
2
Scratch
2
Abscess
2
Folliculitis
2
Streptococcal Infection
2
Inflammation
1
Vasculitis
1
Laser Therapy
1
Skin Cosmetic Procedure
1
Wart Excision
1
Nail Infection
1
Traumatic Ulcer
1
Mole Excision
1
Face Injury
1
Epidermolysis
1
Skin Ulcer
1
Therapeutic Procedure
1
Incision Site Infection
1
Wound Infection Staphylococcal
1

Drug Labels

LabelLabelerEffective
AltabaxPhysicians Total Care, Inc.13-JAN-10
AltabaxRebel Distributors Corp.02-SEP-10
AltabaxGlaxoSmithKline LLC21-JAN-13

Altabax Case Reports

What Altabax safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Altabax. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Altabax.